MFG
AKBA icon

Merit Financial Group’s Akebia Therapeutics AKBA Stock Holding History

Merit Financial Group’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.4K Buy
+14,412
New +$17.2K ﹤0.01% 2337

Other funds holding AKBA

HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
CAMG
CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return
EWS
Eagle Wealth Strategies West Deptford, New Jersey $262M AUM 31.52% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
AWM
Activest Wealth Management Aventure, Florida $518M AUM 44.34% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $420M AUM 22.7% 1-Year Est. Return

Merit Financial Group's AKBA Position: Q2 2026 in Review

Merit Financial Group opened a new position in Akebia Therapeutics (AKBA) in Q2 2026: 14,412 shares worth $16.4K. The stake represents ﹤0.01% of the portfolio and ranks #2337 among its holdings.

9 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Merit Financial Group held 14,412 shares of Akebia Therapeutics worth $16.4K as of Q2 2026.
  • Akebia Therapeutics was a new Merit Financial Group position in Q2 2026.
  • Akebia Therapeutics made up ﹤0.01% of Merit Financial Group's portfolio in Q2 2026, its #2337 holding.
  • 9 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Merit Financial Group's 13F filing for Q2 2026, filed 17 Jul 2026.